Articles by:
Coco Jervis
Featured Article
Sex Drugs for Women: Myths and Marketing Messages
By: Coco Jervis Addyi, FDA Advocacy, Flibanserin, Sex Drugs for Women, Sexual Desire, Sexual Dysfunction Fact Sheets, Health InfoLearn about 5 common myths surrounding sex drugs like Addyi and Viagra as well as the FDA’s approach to this issue.
Browse articles by Coco Jervis
Life After King v. Burwell: Addressing Ongoing Challenges Under the ACA
By: Coco Jervis Affordable Care Act (ACA), Health Care Reform, Health Insurance, Health Insurance Coverage Gap, Raising Women's Voices UncategorizedNow that the Supreme Court Justices have given the Affordable Care Act (ACA) a resounding stamp of approval in their landmark King v. Burwell decision, we can all breath a collective sign of relief. The health care reform law has proven unconquerable by conservatives and is here to stay. Already 16 million more Americans have access to health insurance, thanks to the ACA.
The Great LARC Debate: Facilitating a Balanced Approach to Education and Promotion of LARCs
By: Coco Jervis Birth Control, Intrauterine Device (IUD), Long-Acting Reversible Contraceptives (LARCs), The Women's Health Activist Newsletter Deep Dive ArticlesImmediately after the birth of her twins, 21-year-old Chantal1 had an IUD inserted, at no cost to her. She has had a very positive experience with the IUD, although she had cramping and intermittent bleeding for a couple of weeks after it was inserted. For the most part, though, she describes having her IUD as “smooth sailing.”
FDA Meeting – Generic Drug Labeling
By: Coco Jervis Drug Labeling, FDA Advocacy, Generic Drugs TestimonyStatement of Coco Jervis, J.D., Program Director |
Food and Drug Administration Public Meeting on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products
The FDA’s Hesitation to Approve ‘Female Sexual Dysfunction’ Drugs Isn’t About Sexism
By: Coco Jervis Addyi, Drugs and Devices, FDA Advocacy, Flibanserin, Sex Drugs for Women, Sexual Dysfunction, The Women's Health Activist Newsletter Deep Dive ArticlesThe cultural impact and huge profitability of male-targeted impotence drugs has prompted a rapidly accelerating race to create similar drug treatments for women. Despite more than a decade of research and millions of dollars spent on development, the Food and Drug Administration (FDA) has yet to approve a single drug treatment for cis women dealing with so-called female sexual dysfunction (FSD).
National Women’s Health Network Supports Parity in Generic Drug Labeling
By: Coco Jervis FDA Advocacy, Generic Drug Labeling, Generic Drugs Press ReleasesFOR IMMEDIATE RELEASE
Contact: Coco Jervis 202.407.0788
About the Author
Coco Jervis
Coco Jervis is a former NWHN Program Director. With a focus on AIDS and HIV, and a law degree from Howard University School of Law, she expertly advocates for sexual and reproductive health. Coco continues her activism today as the Grant Manager for the feminist organization MamaCash.